"sectionTitle","id","uuid:ID","name","sectionNumber","text"
"Root","NarrativeContent_1","59f2f7c0-e15c-4e5d-975b-e126fe31e66e","ROOT","0",""
"PROTOCOL SUMMARY","NarrativeContent_2","65bad497-beb3-41b3-bbc8-ca9c36de2890","SECTION 1","1","<div><usdm:ref klass=""StudyIdentifier"" id=""StudyIdentifier_1"" attribute=""studyIdentifier""/></div>"
"Protocol Synopsis","NarrativeContent_3","a25b8c89-a665-4048-9e32-832b6d06c3a4","SECTION 1.1","1.1","<div></div>"
"Trial Schema","NarrativeContent_4","cf5b7aac-866b-47ea-a845-a15c3ecc03e5","SECTION 1.2","1.2","<div></div>"
"Schedule of Activities","NarrativeContent_5","d403341e-5687-4081-aafc-9af5ea5b1e0f","SECTION 1.3","1.3","<div></div>"
"INTRODUCTION","NarrativeContent_6","bd6a320e-ed54-44d3-8c5a-2cccf8eafeae","SECTION 2","2","<div></div>"
"Purpose of Trial","NarrativeContent_7","5b464ac5-e7d4-420d-85b2-21f1bd525c02","SECTION 2.1","2.1","<div></div>"
"Summary of Benefits and Risks","NarrativeContent_8","2d24c657-3bf9-40a0-a789-b20a41101856","SECTION 2.2","2.2","<div></div>"
"TRIAL OBJECTIVES, ENDPOINTS AND ESTIMANDS","NarrativeContent_9","d3a42858-75f6-4ddc-adb9-dbba5f8ee9a8","SECTION 3","3","<div></div>"
"Primary Objectives","NarrativeContent_10","b0104a2b-cf24-4d49-8f82-ab2d09d66305","SECTION 3.1","3.1","<div><table>
  <tr>
    <th style=""vertical-align: top"">Primary Objective</th>
    <th style=""vertical-align: top"">Primary Endpoint</th>
  </tr>
  <tr>
    <td style=""vertical-align: top""><usdm:ref klass=""Objective"" namexref=""OBJ1"" attribute=""description""/></td>
    <td style=""vertical-align: top""><usdm:ref klass=""Endpoint"" id=""Endpoint_1"" attribute=""description""/></td>
  </tr>
</table></div>"
"TRIAL DESIGN","NarrativeContent_11","a4e433bd-c602-40c3-a61a-6ef26b7456d2","SECTION 4","4","<div></div>"
"Description of Trial Design","NarrativeContent_12","79b1b752-9ddd-47fc-8ea2-4d2bea3497fb","SECTION 4.1","4.1","<div></div>"
"Participant Input into Design","NarrativeContent_13","7fec3ed8-14a6-4d9c-a2ce-388f9b69748b","SECTION 4.1.1","4.1.1","<div></div>"
"Rationale for Trial Design","NarrativeContent_14","c19dd889-b936-4bc6-be52-379b230e1a29","SECTION 4.2","4.2","<div></div>"
"Rationale for Comparator","NarrativeContent_15","24a5a148-01f7-4368-ba1e-ab4c8ded34c2","SECTION 4.2.1","4.2.1","<div></div>"
"Rationale for Adaptive or Novel Trial Design","NarrativeContent_16","93c85a22-649f-4890-82e3-e59870ed98a6","SECTION 4.2.2","4.2.2","<div></div>"
"Other Trial Design Considerations","NarrativeContent_17","3321fb84-39bf-475e-b15b-f91621b7e26d","SECTION 4.2.3","4.2.3","<div></div>"
"Access to Trial Intervention After End of Trial","NarrativeContent_18","5e9f272d-039d-4f3f-b2e9-adc377c9b13d","SECTION 4.3","4.3","<div></div>"
"Start of Trial and End of Trial","NarrativeContent_19","2a6892b8-b244-4af8-94b4-7b6cac62443c","SECTION 4.4","4.4","<div></div>"
"TRIAL POPULATION","NarrativeContent_20","c05bdb56-08e8-4df6-8a29-14e31f67bb82","SECTION 5","5","<div></div>"
"Selection of Trial Population","NarrativeContent_21","a0942b1f-e1f4-44ca-a73a-0c34957a50f6","SECTION 5.1","5.1","<div></div>"
"Rationale for Trial Population","NarrativeContent_22","c8bf1b12-164b-4ba9-816f-256d22aedb9b","SECTION 5.2","5.2","<div></div>"
"Inclusion Criteria","NarrativeContent_23","4564cff8-117b-4d50-b394-676e80fcd2e2","SECTION 5.3","5.3","<div><p>Inclusion criteria are:</p>
<ul>
  <li>1. Something</li>
  <li>2. Something else</li>
</ul></div>"
"Exclusion Criteria","NarrativeContent_24","f981c884-5f20-437a-9715-f23540812a7c","SECTION 5.4","5.4","<div><p>Exclusion criteria are:</p>
<ul>
  <li>1. Dont do this</li>
  <li>2. And don't do that</li>
</ul></div>"
"Lifestyle Considerations","NarrativeContent_25","8e4a0db7-9812-4142-8716-10d3a221eba7","SECTION 5.5","5.5","<div></div>"
"Meals and Dietary Restrictions","NarrativeContent_26","f83056c7-2ad6-4afa-9181-0909dc9b74bc","SECTION 5.5.1","5.5.1","<div></div>"
"Caffeine, Alcohol, Tobacco, and Other Habits","NarrativeContent_27","c7394d00-a4d5-4cce-accd-a28b46dd683b","SECTION 5.5.2","5.5.2","<div></div>"
"Physical Activity","NarrativeContent_28","581271c5-3fff-4e9d-aa9a-dc018304c993","SECTION 5.5.3","5.5.3","<div></div>"
"Other Activity","NarrativeContent_29","4448ec56-1b82-4d04-8ac2-6463cdd09073","SECTION 5.5.4","5.5.4","<div></div>"
"Screen Failures","NarrativeContent_30","e9a32407-a4b2-473c-9624-7bef8e8b046d","SECTION 5.6","5.6","<div></div>"
"TRIAL INTERVENTION AND CONCOMITANT THERAPY","NarrativeContent_31","019fd404-c684-46c4-9ccc-a83bbb4bd372","SECTION 6","6","<div></div>"
"Description of Trial Intervention","NarrativeContent_32","fbd50ac4-061d-41f0-8e7a-2be9bc349a05","SECTION 6.1","6.1","<div></div>"
"Rationale for Trial Intervention","NarrativeContent_33","23fda0e2-4e0d-4373-9967-968965d9e09f","SECTION 6.2","6.2","<div></div>"
"Dosing and Administration","NarrativeContent_34","00d9b40f-01f6-4343-9975-c5af2b0cb350","SECTION 6.3","6.3","<div></div>"
"Trial Intervention Dose Modification","NarrativeContent_35","f764799c-3305-4b6f-9e1f-40fbfcf0b83a","SECTION 6.3.1","6.3.1","<div></div>"
"Treatment of Overdose","NarrativeContent_36","379496b9-ecd6-4bf7-a50f-838fb85c9a97","SECTION 6.4","6.4","<div></div>"
"Preparation, Handling, Storage and Accountability","NarrativeContent_37","1678fa9b-d021-4d5b-b4a3-4306902a69ba","SECTION 6.5","6.5","<div></div>"
"Preparation of Trial Intervention","NarrativeContent_38","de665279-5cab-4beb-9d41-a38e94d62093","SECTION 6.5.1","6.5.1","<div></div>"
"Handling and Storage of Trial Intervention","NarrativeContent_39","81f72a0c-9b5b-4af1-a19c-8841e460e5be","SECTION 6.5.2","6.5.2","<div></div>"
"Accountability of Trial Intervention","NarrativeContent_40","e09872ab-6a0d-49a0-89cc-caf22c978efc","SECTION 6.5.3","6.5.3","<div></div>"
"Participant Assignment, Randomisation and Blinding","NarrativeContent_41","e633d30d-1cc6-4397-b946-893a21ae56e8","SECTION 6.6","6.6","<div></div>"
"Participant Assignment","NarrativeContent_42","d2f72500-ccdc-4f56-91b0-07015ab8665f","SECTION 6.6.1","6.6.1","<div></div>"
"Randomisation","NarrativeContent_43","935a342f-985f-4611-b7ea-edc4efe8d12c","SECTION 6.6.2","6.6.2","<div></div>"
"Blinding and Unblinding","NarrativeContent_44","3d82071b-455d-47f1-879d-f325c745f312","SECTION 6.6.3","6.6.3","<div><p>Blinding and unblinding text here please</p></div>"
"Trial Intervention Compliance","NarrativeContent_45","85b973a2-2b54-4a3c-9afb-72c412f14aac","SECTION 6.7","6.7","<div></div>"
"Concomitant Therapy","NarrativeContent_46","3042ab1b-2601-4869-a3f4-5141054194a9","SECTION 6.8","6.8","<div></div>"
"Prohibited Concomitant Therapy","NarrativeContent_47","abccb52a-f387-42eb-a245-caf03679a287","SECTION 6.8.1","6.8.1","<div></div>"
"Permitted Concomitant Therapy","NarrativeContent_48","b65092f0-34cf-463b-822b-aa4ff2eae138","SECTION 6.8.2","6.8.2","<div></div>"
"Rescue Therapy","NarrativeContent_49","48cbca6b-49db-40d2-9d66-6c713aeee5c9","SECTION 6.8.3","6.8.3","<div></div>"
"Other Therapy","NarrativeContent_50","5c7cc98e-6127-4be3-ba2d-aab55f4573b7","SECTION 6.8.4","6.8.4","<div></div>"
"DISCONTINUATION OF TRIAL INTERVENTION AND PARTICIPANT WITHDRAWAL FROM TRIAL","NarrativeContent_51","0963954b-a610-45fb-9036-48efc8a99823","SECTION 7","7","<div></div>"
"Discontinuation of Trial Intervention","NarrativeContent_52","3b218b5d-8df4-44e7-a41c-db7fa321ac5c","SECTION 7.1","7.1","<div></div>"
"Criteria for Permanent Discontinuation of Trial Intervention","NarrativeContent_53","377d5749-6322-4cff-b81d-f9badf745850","SECTION 7.1.1","7.1.1","<div></div>"
"Temporary Discontinuation or Interruption of Trial Intervention","NarrativeContent_54","1ece062a-8414-411b-953c-0359322ef7a5","SECTION 7.1.2","7.1.2","<div></div>"
"Rechallenge","NarrativeContent_55","20a996c0-e74d-4a9e-8d39-2253af066fee","SECTION 7.1.3","7.1.3","<div></div>"
"Participant Withdrawal from the Trial","NarrativeContent_56","af2742b0-71e9-494e-9c2e-67fdc2103e2b","SECTION 7.2","7.2","<div></div>"
"Lost to Follow-Up","NarrativeContent_57","5eb41e90-e90f-4f57-8449-6577581efbb5","SECTION 7.3","7.3","<div></div>"
"Trial Stopping Rules","NarrativeContent_58","feabf7c3-d39b-4fd2-a962-2b2fcf441981","SECTION 7.4","7.4","<div></div>"
"TRIAL ASSESSMENTS AND PROCEDURES","NarrativeContent_59","29e43568-7884-44c3-90a1-39ba747cbb67","SECTION 8","8","<div></div>"
"Screening/Baseline Assessments and Procedures","NarrativeContent_60","7bebe85d-d2e2-42bd-8c3d-bf1cf9b336ff","SECTION 8.1","8.1","<div></div>"
"Efficacy Assessments and Procedures","NarrativeContent_61","6164e501-0c5e-41f4-a722-13be71be670d","SECTION 8.2","8.2","<div></div>"
"Safety Assessments and Procedures","NarrativeContent_62","be15f0c4-e2a4-45c6-829f-b31647ab4d95","SECTION 8.3","8.3","<div></div>"
"Physical Examination","NarrativeContent_63","c244778c-81a0-4887-b220-68afdee77f21","SECTION 8.3.1","8.3.1","<div></div>"
"Vital Signs","NarrativeContent_64","5a353415-81f8-488d-a1b8-bcd40dc85b04","SECTION 8.3.2","8.3.2","<div></div>"
"Electrocardiograms","NarrativeContent_65","5e044e31-89db-4048-b1a8-7a682959ad2c","SECTION 8.3.3","8.3.3","<div></div>"
"Clinical Laboratory Assessments","NarrativeContent_66","82786664-0905-47b6-b9ad-e7ac6275cca5","SECTION 8.3.4","8.3.4","<div></div>"
"Suicidal Ideation and Behaviour Risk Monitoring","NarrativeContent_67","bfd3622d-97bc-4305-a1b8-18957c4ab999","SECTION 8.3.5","8.3.5","<div></div>"
"Adverse Events and Serious Adverse Events","NarrativeContent_68","07a5d7cc-2dbd-4ad5-ae84-d23a1dedbf5e","SECTION 8.4","8.4","<div></div>"
"Definitions of AE and SAE","NarrativeContent_69","32159034-eb8a-466d-bc63-cbd72c969ee9","SECTION 8.4.1","8.4.1","<div></div>"
"Time Period and Frequency for Collecting AE and SAE Information","NarrativeContent_70","81270bb6-8176-42f2-a53d-8a2d8b0717d7","SECTION 8.4.2","8.4.2","<div></div>"
"Identifying AEs and SAEs","NarrativeContent_71","3b936c05-3ed1-4e89-9f6b-d6e30e8371ea","SECTION 8.4.3","8.4.3","<div></div>"
"Recording of AEs and SAEs","NarrativeContent_72","f9c9b794-aba1-480c-a969-7e99b7cb94a1","SECTION 8.4.4","8.4.4","<div></div>"
"Follow-up of AEs and SAEs","NarrativeContent_73","64b4908f-b971-4abe-915f-f41426f94d6f","SECTION 8.4.5","8.4.5","<div></div>"
"Reporting of SAEs","NarrativeContent_74","5092395b-390e-424c-972f-98bf68d1a3c8","SECTION 8.4.6","8.4.6","<div></div>"
"Regulatory Reporting Requirements for SAEs","NarrativeContent_75","51699b78-fa84-46b1-b06f-e0c547168076","SECTION 8.4.7","8.4.7","<div></div>"
"Serious and Unexpected Adverse Reaction Reporting","NarrativeContent_76","639abba9-16d6-4d26-9781-929f760624f6","SECTION 8.4.8","8.4.8","<div></div>"
"Adverse Events of Special Interest","NarrativeContent_77","e0590afe-25c6-4f90-bb24-00ded5f43749","SECTION 8.4.9","8.4.9","<div></div>"
"Disease-related Events or Outcomes Not Qualifying as AEs or SAEs","NarrativeContent_78","fef4d633-19dd-4339-83ad-cd19fc6060fc","SECTION 8.4.10","8.4.10","<div></div>"
"Pregnancy and Postpartum Information","NarrativeContent_79","aae05e90-8c18-4b86-b622-5c5cef941b99","SECTION 8.5","8.5","<div></div>"
"Participants Who Become Pregnant During the Trial","NarrativeContent_80","a748fac3-9bd3-44d5-bb1f-6496eb3b3bc4","SECTION 8.5.1","8.5.1","<div></div>"
"Participants Whose Partners Become Pregnant","NarrativeContent_81","ece44ee2-2e26-47aa-834a-4a201367025a","SECTION 8.5.2","8.5.2","<div></div>"
"Medical Device Product Complaints for Drug/Device Combination Products","NarrativeContent_82","3fb7d6fb-fb9e-490e-824b-d6230e699a78","SECTION 8.6","8.6","<div></div>"
"Definition of Medical Device Product Complaints","NarrativeContent_83","b383509c-6eea-48c6-a8b3-84ced5bf2e49","SECTION 8.6.1","8.6.1","<div></div>"
"Recording of Medical Device Product Complaints","NarrativeContent_84","2cf180aa-fc26-4973-975a-d96eb3063aaf","SECTION 8.6.2","8.6.2","<div></div>"
"Time Period and Frequency for Collecting Medical Device Product Complaints .","NarrativeContent_85","cb765269-3798-4aec-af22-d7d7e8f89bee","SECTION 8.6.3","8.6.3","<div></div>"
"Follow-Up of Medical Device Product Complaints","NarrativeContent_86","e947de7a-76b8-4b67-a2c2-4b4d37090f99","SECTION 8.6.4","8.6.4","<div></div>"
"Regulatory Reporting Requirements for Medical Device Product Complaints","NarrativeContent_87","84f0d0d2-5911-4e32-97d9-1974fbf1d245","SECTION 8.6.5","8.6.5","<div></div>"
"Pharmacokinetics","NarrativeContent_88","ac3454f3-4590-4918-b03a-3c1f3e2dfdd8","SECTION 8.7","8.7","<div></div>"
"Genetics","NarrativeContent_89","43dcacb4-0683-4110-a23c-10c60e2b698c","SECTION 8.8","8.8","<div></div>"
"Biomarkers","NarrativeContent_90","86143ac5-abd5-4cca-9dd5-65b962123ca8","SECTION 8.9","8.9","<div></div>"
"Immunogenicity Assessments","NarrativeContent_91","d9f33ee9-249c-4dcb-8a13-13de4dccd577","SECTION 8.1","8.1","<div></div>"
"Medical Resource Utilisation and Health Economics","NarrativeContent_92","0b53efde-c4d2-4637-8846-92b5e0880e9d","SECTION 8.1.1","8.1.1","<div></div>"
"STATISTICAL CONSIDERATIONS","NarrativeContent_93","4ecf5e34-acec-4281-a418-05db2adb3251","SECTION 9","9","<div></div>"
"Analysis Sets","NarrativeContent_94","8996cdfc-34fb-4138-a047-8219cd08c3b3","SECTION 9.1","9.1","<div></div>"
"Analyses Supporting Primary Objective(s)","NarrativeContent_95","3a6597a3-26d1-466f-b58e-baab402a7c33","SECTION 9.2","9.2","<div></div>"
"Statistical Model, Hypothesis, and Method of Analysis","NarrativeContent_96","72e60b21-eea6-4b89-9e07-b1379343e9ba","SECTION 9.2.1","9.2.1","<div></div>"
"Handling of Intercurrent Events of Primary Estimand(s)","NarrativeContent_97","f2b66a26-8696-429b-88c8-cb217a9a6b1b","SECTION 9.2.2","9.2.2","<div></div>"
"Handling of Missing Data","NarrativeContent_98","a5a6b3b1-1d75-4b5d-a15e-77a5c2a74e6e","SECTION 9.2.3","9.2.3","<div></div>"
"Sensitivity Analysis","NarrativeContent_99","89978193-90f0-44a2-96b8-de07adcd885a","SECTION 9.2.4","9.2.4","<div></div>"
"Supplementary Analysis","NarrativeContent_100","f4e0bcbc-a949-43e4-8fb9-b637e5dd5ace","SECTION 9.2.5","9.2.5","<div></div>"
"Analysis Supporting Secondary Objective(s)","NarrativeContent_101","a715c295-d6c0-420b-9b22-b8f8b439706d","SECTION 9.3","9.3","<div></div>"
"Analysis of Exploratory Objective(s)","NarrativeContent_102","77d3f857-1cbf-4094-af0c-abd4fdbc0a23","SECTION 9.4","9.4","<div></div>"
"Safety Analyses","NarrativeContent_103","6954c691-ae7d-45ac-a7ba-8b86ca40a517","SECTION 9.5","9.5","<div></div>"
"Other Analyses","NarrativeContent_104","5acfbca3-72a1-49df-8810-ca2197d9339f","SECTION 9.6","9.6","<div></div>"
"Interim Analyses","NarrativeContent_105","b515f6a5-b907-47c0-aac2-2df619d75b57","SECTION 9.7","9.7","<div></div>"
"Sample Size Determination","NarrativeContent_106","8db7de78-c47f-42dd-8ff7-8b535357dba5","SECTION 9.8","9.8","<div></div>"
"Protocol Deviations","NarrativeContent_107","eb3cdb6b-2cc8-415c-b2a6-c13cb4101167","SECTION 9.9","9.9","<div></div>"
"GENERAL CONSIDERATIONS: REGULATORY, ETHICAL, AND TRIAL OVERSIGHT","NarrativeContent_108","5eee1ce6-1eb9-45aa-9647-f11a681e470e","SECTION 10","10","<div></div>"
"Regulatory and Ethical Considerations","NarrativeContent_109","6c3b54ec-4edd-40e7-9adc-7a770ef042cf","SECTION 10.1","10.1","<div></div>"
"Committees","NarrativeContent_110","a3b0d6d2-1b08-459b-aa03-e6f9255004d7","SECTION 10.2","10.2","<div></div>"
"Informed Consent Process","NarrativeContent_111","a8045b12-2415-40b8-94b9-57bfba0e1a49","SECTION 10.3","10.3","<div></div>"
"Data Protection","NarrativeContent_112","f3ae1f83-1e31-4687-a71d-bdfd32a95a28","SECTION 10.4","10.4","<div></div>"
"Early Site Closure or Trial Termination","NarrativeContent_113","6714002f-38fd-4dbc-b49a-be162faea1a4","SECTION 10.5","10.5","<div></div>"
"GENERAL CONSIDERATIONS: RISK MANAGEMENT AND QUALITY ASSURANCE","NarrativeContent_114","8721da41-2ab5-4b65-a2c2-d1597b333ed5","SECTION 11","11","<div></div>"
"Quality Tolerance Limits","NarrativeContent_115","bdd851a6-e8ff-4325-b35b-433017c36827","SECTION 11.1","11.1","<div></div>"
"Data Quality Assurance","NarrativeContent_116","a7bb5138-b02d-41ce-8392-90db84256c70","SECTION 11.2","11.2","<div></div>"
"Source Data","NarrativeContent_117","d0bd8d78-cc73-4bc9-8c86-16df5e91bfbe","SECTION 11.3","11.3","<div></div>"
"APPENDIX: ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS - DEFINITIONS, SEVERITY, AND CAUSALITY","NarrativeContent_118","11a5f06f-824b-48f7-8735-b5c6d10601a8","SECTION 12","12","<div></div>"
"Further Details and Clarifications on the AE Definition","NarrativeContent_119","8a972039-8ce4-484c-bb76-62b3a8ebfc69","SECTION 12.1","12.1","<div></div>"
"Further Details and Clarifications on the SAE Definition","NarrativeContent_120","886b7bd3-d5c4-4b77-8711-3a1833ab19f4","SECTION 12.2","12.2","<div></div>"
"Severity","NarrativeContent_121","8d017c37-0da8-4fe1-98ba-d6d5eedef021","SECTION 12.3","12.3","<div></div>"
"Causality","NarrativeContent_122","896ddf12-eabe-4001-9628-65149e92796d","SECTION 12.4","12.4","<div></div>"
"APPENDIX: DEFINITIONS AND SUPPORTING OPERATIONAL DETAILS","NarrativeContent_123","2cbff5c6-fc57-40f2-ae2f-f9d8339586ac","SECTION 13","13","<div></div>"
"Contraception and Pregnancy Testing","NarrativeContent_124","fa85bca3-c481-4b35-84ee-893fd40bdd65","SECTION 13.1","13.1","<div></div>"
"Definitions Related to Childbearing Potential","NarrativeContent_125","a8c7a3f4-8c0c-4c37-bded-fb78de587e18","SECTION 13.1.1","13.1.1","<div></div>"
"Contraception","NarrativeContent_126","0e0d0ce6-79a4-43a9-aebd-d981f2d3c3c4","SECTION 13.1.2","13.1.2","<div></div>"
"Pregnancy Testing","NarrativeContent_127","de1e544d-3e00-47ae-8c6d-0c4e9706d3b5","SECTION 13.1.3","13.1.3","<div></div>"
"Clinical Laboratory Tests","NarrativeContent_128","e79f44eb-e585-4d97-abad-e99fd76260c0","SECTION 13.2","13.2","<div></div>"
"Country/Region-Specific Differences","NarrativeContent_129","3c59f0ff-5fb1-42d7-ad4b-0c953dba1df2","SECTION 13.3","13.3","<div></div>"
"Prior Protocol Amendments","NarrativeContent_130","6686e9ba-e06b-4544-b148-c2b5c32f7efc","SECTION 13.4","13.4","<div></div>"
"APPENDIX: GLOSSARY OF TERMS","NarrativeContent_131","9a8a6ec5-bfc2-4c9b-8e05-3b1d55508d02","SECTION 14","14","<div></div>"
"APPENDIX: REFERENCES","NarrativeContent_132","bfe18ab1-2308-40d2-8310-5a0aae3fc5e4","SECTION 15","15","<div></div>"
